TABLE 2.

Variables associated with mortality in 294 patients with candidemia

Characteristic (no. of patients [%])aNo. of patients who:OR (95% CI)Pb
Died (n = 154)Survived (n = 140)
Age (yr) (mean ± SD)69 ± 1259 ± 16<0.001
Male sex70 (45.4)54 (38.5)1.32 (0.81-2.17)0.23
Hospital-acquired candidemia144 (93.5)118 (84.2)2.68 (1.16-6.59)0.01
Neutropeniac10 (6.5)8 (5.7)1.14 (0.39-3.44)0.78
Immunosuppressive therapy75 (48.7)45 (32.1)2.00 (1.21-3.31)0.003
Duration of hospitalization (no. of days) (mean ± SD)d46 ± 3951 ± 400.27
Surgical admission87 (56.4)75 (53.5)1.12 (0.69-1.83)0.61
In the ICU at diagnosis52 (33.7)50 (35.7)0.91 (0.55-1.52)0.72
TPN72 (46.7)66 (47.1)0.98 (0.60-1.59)0.94
CVC123 (79.8)90 (64.2)2.20 (1.26-3.86)0.003
Catheter-related candidemia26 (16.8)34 (24.2)0.63 (0.34-1.16)0.11
APACHE III score (mean ± SD)38 ± 1627 ± 17<0.001
Species isolated
    Candida albicans97 (62.9)71 (50.7)1.65 (1.01-2.70)0.03
    Candida parapsilosis24 (15.5)40 (28.5)0.46 (0.25-0.84)0.007
    Candida tropicalis12 (7.8)16 (11.4)0.65 (0.27-1.54)0.28
    Candida glabrata15 (9.7)11 (7.8)1.26 (0.52-3.16)0.57
    Other Candida species6 (3.8)2 (1.4)1.44 (0.95-2.18)0.19
Biofilm production by fungal isolatee56 (36.3)24 (17.1)2.76 (1.54-5.00)<0.001
Inadequate antifungal therapy30 (19.4)13 (9.3)2.36 (1.13-5.16)0.01
  • a Values are presented as the number (percentage) of patients with the specified characteristic, unless otherwise indicated.

  • b P value comparing the value for patients who died to the value for patients who survived.

  • c White blood cell count of less than 0.5 × 109 cells/liter.

  • d For patients transferred from another hospital, the duration of hospitalization was calculated by the date of the first hospital admission.

  • e As assessed by %T and XTT absorbance determinations (see Materials and Methods for details).